SCHEMBL12075314

SCHEMBL12075314

O=c1ccc2cc3c(cc2o1)OC[C@H](I)O3

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.65
▸ ALDH1A1 P00352 10/20 0.65
▸ HPGD P15428 8/20 0.65
▸ HSD17B10 Q99714 7/20 0.65
▸ ACHE P22303 5/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ GAA P10253 6/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CA12 O43570 5/20 0.42
▸ CA9 Q16790 5/20 0.42
▸ MCL1 Q07820 4/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ GLA P06280 2/20 0.42
▸ AKR1B1 P15121 2/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ CASP7 P55210 2/20 0.42
▸ ERAP1 Q9NZ08 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6664850 0.80 ALDH1A1 (0.63) KDM4EALDH1A1HPGDHSD17B10ACHE
SCHEMBL6664851 0.80 ALDH1A1 (0.63) KDM4EALDH1A1HPGDHSD17B10ACHE
Dihydro-Obliquin SCHEMBL12062091 0.79 ALDH1A1 (1.00) KDM4EALDH1A1HPGDHSD17B10ACHE
SCHEMBL6843275 0.77 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ACHE
Ayapin SCHEMBL6694210 0.77 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ACHE
Ayapin SCHEMBL30171405 0.77 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ACHE
Obliquin SCHEMBL12062102 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10ACHE
Obliquin SCHEMBL29534204 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10ACHE
Obliquin SCHEMBL2255488 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10ACHE
SCHEMBL28994323 0.71 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-30 — — US disclosed
WO-2011094016-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY (US) 2011-08-04 — — WO disclosed
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY 2011-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF TYR, MC1R, MITF KDM4E 79/4885ALDH1A1 246/4885HPGD 2055/4885
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING TYR, MC1R, MITF KDM4E 274/4885ALDH1A1 397/4885HPGD 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback